Safety of switching between rituximab biosimilars in cancer

Posted 07/05/2021

In more than 10 years of clinical experience, no substantial clinical and safety differences have been detected among biosimilars and their already approved...

more
New in vitro–in vivo simulations predict generi... Generics/Research | Posted 07/05/2021
Study supports advanced IV preparation and stor... Biosimilars/Research | Posted 07/05/2021
Samsung Bioepis launches Hadlima in Australia a... Biosimilars/News | Posted 07/05/2021
Insurer formularies increase complexity for hea... Biosimilars/General | Posted 07/05/2021
EMA recommends approval of abiraterone and iofl... Generics/News | Posted 07/05/2021
EU Court of Justice upholds Lundbeck fines over... Policies & Legislation | Posted 07/05/2021
A positive outlook for the US biosimilars market Biosimilars/Research | Posted 30/04/2021
LG Chem gains approval for adalimumab biosimila... Biosimilars/News | Posted 30/04/2021
The future of copy biologicals in China Reports | Posted 30/04/2021
Rheumatoid arthritis treatments in Australia Biosimilars/General | Posted 30/04/2021
Expanding access to trastuzumab biological trea... Biosimilars/Research | Posted 30/04/2021
Colorado to import drugs from Canada and beyond Policies & Legislation | Posted 30/04/2021
Generics in India Generics/General | Posted 30/04/2021
CADTH summarizes evidence on switching to etane... Biosimilars/Research | Posted 23/04/2021
EC approval for bevacizumab biosimilar Alymsys/... Biosimilars/News | Posted 23/04/2021
Relieving the economic burden on EU healthcare... Biosimilars/Research | Posted 23/04/2021
Biosimilars of enoxaparin sodium Biosimilars/General | Posted 23/04/2021
Tentative US approval for Symbicort generic Generics/News | Posted 23/04/2021
Federal Court maintains decision on infliximab... Policies & Legislation | Posted 23/04/2021
Characteristics associated with biosimilar use... Biosimilars/Research | Posted 16/04/2021
British Columbia adds adalimumab to biosimilar... Biosimilars/General | Posted 16/04/2021
Biosimilars in the treatment of psoriasis Biosimilars/Research | Posted 16/04/2021
Advances for Formycon and Alteogen’s eye diseas... Biosimilars/News | Posted 16/04/2021
Teva not liable in US due to FDCA implied preem... Policies & Legislation | Posted 16/04/2021
US$1.2 FDA contract for generic drug computatio... Generics/General | Posted 16/04/2021
Adalimumab biosimilar FKB327 causes less pain t... Biosimilars/Research | Posted 09/04/2021
New partnerships for Cipla and Samsung Bioepis Pharma News | Posted 09/04/2021
Biosimilars regulation, clinical trials, approv... Biosimilars/Research | Posted 09/04/2021
FDA accepts application for adalimumab biosimil... Biosimilars/News | Posted 09/04/2021
Biosimilars of ustekinumab Biosimilars/General | Posted 09/04/2021
Dispensing branded drugs costs Medicare over a... Generics/Research | Posted 09/04/2021
China improves generics injection consistency e... Policies & Legislation | Posted 09/04/2021
Etanercept biosimilar injection pen, YLB113, co... Biosimilars/Research | Posted 02/04/2021
Technological approaches to drug repurposing fo... Generics/Research | Posted 02/04/2021
Samsung Bioepis and Eden Biologics announce new... Biosimilars/Research | Posted 02/04/2021
Australian and Indian approval for teriparatide... Biosimilars/News | Posted 02/04/2021
Biosimilars of aflibercept Biosimilars/General | Posted 02/04/2021
EMA recommends approval of abiraterone and thio... Generics/News | Posted 02/04/2021
Biosimilars in Europe: prescriber survey Biosimilars/Research | Posted 26/03/2021
Argentina approves bevacizumab similar biologic... Biosimilars/News | Posted 26/03/2021
more

NON-BIOLOGICAL COMPLEX DRUGS

FDA issues final guidance on liposome drug products Posted 27/04/2018

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft...

more


FDA approves 40 mg follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 09/03/2018
Mylan launches first follow-on glatiramer aceta... Non‐Biological Complex Drugs/News | Posted 15/02/2018
Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 04/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015
more

Generics News Research General

more

Biosimilars News Research General

more